Voluntary MFN agreement modelling, new in SyMAP 2.0 →
SyMAP MFN: Most Favored Nation Drug Pricing Software
Model all four US MFN pathways (GENEROUS, GLOBE, GUARD, and voluntary manufacturer agreements) and forecast your revenue under every policy scenario.
One toolkit for every US MFN pathway
SyMAP MFN models Most Favored Nation drug pricing across US government payer programs and beyond. As MFN policy reshapes pharmaceutical pricing through international reference benchmarks, SyMAP MFN brings together four integrated models: the CMS GENEROUS Model for Medicaid, the GLOBE Model for Medicare Part B, the GUARD Model for Medicare Part D, and (new in SyMAP 2.0) voluntary manufacturer MFN agreements, the deal structure driving the current wave of manufacturer announcements analysed in the CEA’s $600B report. Analyse, simulate, and respond strategically, program by program or across your whole portfolio.
Four integrated MFN models
MFN Use Cases
Voluntary Agreement Decisions
Quantify what signing a voluntary MFN agreement would mean for your portfolio (drug by drug, pillar by pillar) before you negotiate.
Cross-Program MFN Impact Analysis
Model MFN pricing impacts across Medicare Part B, Part D, Medicaid, and voluntary pathways on one portfolio.
Global-to-US MFN Strategy
Optimise international pricing strategy for US MFN benchmark management, joined up end-to-end in SyMAP Global Pricing.
Policy Scenario Planning
Forecast your US revenue under voluntary, CMS, and baseline policy paths, and see which channels carry the exposure.
SyMAP MFN FAQs
- What is SyMAP MFN?
- SyMAP MFN is our comprehensive platform for Most Favored Nation (MFN) drug pricing analysis. It brings together four integrated models: the GENEROUS Model for Medicaid, the GLOBE Model for Medicare Part B, the GUARD Model for Medicare Part D, and voluntary manufacturer MFN agreements. SyMAP MFN provides cross-program exposure analysis, rebate and revenue modelling, policy-scenario forecasting, and strategic scenario planning. Explore our MFN Hub for the latest resources, tools, and policy updates.
- Can SyMAP model voluntary MFN agreements?
- Yes, this is new in SyMAP 2.0. The Voluntary model implements the voluntary manufacturer agreement structure: each drug resolves to the appropriate pillar automatically (existing portfolio drugs to the Medicaid pillar, new launches to the Prospective pillar) based on its US launch timing relative to the agreement start date, with per-drug overrides available. Agreement start dates, participation timing, and the channels in scope are all configurable per scenario.
- What is the CMS GENEROUS Model?
- The GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid) is a voluntary CMS demonstration program running from January 2026 through 2030. It introduces Most Favored Nation (MFN) pricing to Medicaid by using PPP-adjusted net prices from 8 reference countries to calculate supplemental rebates. The benchmark is set by the 2nd lowest price, and manufacturers must achieve a Guaranteed Net Unit Price (GNUP). SyMAP MFN includes full GENEROUS modelling capabilities. Learn more at our MFN Hub.
- What is the GLOBE Model for Medicare Part B MFN pricing?
- The GLOBE Model is a proposed MFN policy for Medicare Part B that embeds international price benchmarks into reimbursement for physician-administered drugs. Starting October 2026, GLOBE would reference 19 OECD nations, allowing manufacturers to choose between Method I (public list prices) or Method II (volume-weighted net prices), using the higher of the two with PPP adjustments. SyMAP MFN models GLOBE exposure alongside GENEROUS, GUARD, and Voluntary.
- What is the GUARD Model for Medicare Part D MFN pricing?
- The GUARD Model is a proposed MFN policy for Medicare Part D that embeds international benchmarks into inflation-rebate calculations for self-administered retail pharmacy drugs. Proposed to start January 2027, GUARD references 19 OECD countries and uses Method I/II methodology (the higher of the two, with PPP adjustments). SyMAP MFN models GUARD exposure alongside GENEROUS, GLOBE, and Voluntary.
- What reference countries are used in the MFN models?
- The MFN models use different reference country baskets. GENEROUS uses 8 countries: Canada, France, Germany, Italy, Japan, UK, Denmark, and Switzerland (G-7 excluding USA, plus Denmark and Switzerland). GUARD and GLOBE use 19 OECD nations: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and UK. SyMAP MFN models all reference relationships across these baskets.
- Can I model partial GENEROUS participation?
- Yes. SyMAP MFN includes a participation period slider that lets you select specific years (e.g., 2027 to 2029) to model scenarios where you join the GENEROUS Model late or withdraw early from MFN pricing obligations.
- Can SyMAP model pharmaceutical tariffs?
- Yes. The Section 232 tariff overlay applies tariff assumptions across forecast and comparison views, so you can assess tariff exposure alongside MFN policy impacts in one coherent scenario.
- How does SyMAP MFN help with cross-program MFN analysis?
- SyMAP MFN provides a unified view of MFN exposure across GENEROUS, GLOBE, GUARD, and voluntary agreements. You can analyse how a single ex-US pricing decision impacts supplemental rebates in Medicaid, Part B reimbursement, Part D inflation rebates, and voluntary agreement outcomes simultaneously, and compare policy scenarios side by side. Try our interactive tools at the MFN Hub.